Similarly, reduced major kidney endpoints in people with diabetes on GLP-1RAs were found in a nationwide Taiwanese cohort of 7279 propensity-matched pairs, with a comparator group taking long-acting insulin.86 Chen et al87 examined a retrospective cohort of 27 279 nontransplant KF with diabetes on dipeptidyl peptidase-4 inhibitors or GLP-1RAs, and compared their risk of all-cause, sepsis-related or infection-related mortality. The gene discussed is DPP4; the disease is diabetes mellitus.